Originally published by our sister publication Gastroenterology & Endoscopy News
By GEN Staff
The FDA approved the ileal bile acid transporter inhibitor maralixibat (Livmarli, Mirum) for cholestatic pruritus in patients 5 years of age and older with progressive familial intrahepatic cholestasis.
Maralixibat, which is already approved for cholestatic pruritus in patients 3 months of age and older with Alagille syndrome, works to limit the reabsorption of bile acids from the terminal